New eye mite focus for Glaukos puts it in competition with Tarsus Pharmaceuticals
DRUGMAKERS: Tarsus CEO expects to be first
■ By AUDREY KEMP
Two big Orange County companies have set their sights on combating tiny Demodex mites that often nest among eyelids.
San Clemente ophthalmic device maker Glaukos Corp. (NYSE: GKOS) recently entered a $5 million licensing agreement with Attillaps Holdings Inc. of Denver to research, develop, manufacture and commercialize investigational therapies for Demodex blepharitis, which occurs when mites infest the follicles of the face and eyelids, causing irritation and dry eyes.
The disease can lead to corneal damage, blurred vision and blindness.
While the disease is estimated to account for over half of the 45 million patients who visit eye care
TABLE OF CONTENTS
en-us
2021-11-29T08:00:00.0000000Z
2021-11-29T08:00:00.0000000Z
https://ocbusinessjournal.pressreader.com/article/281663963279654
LABJ